Recent 8-K filings for AKTS

• August 13, 2026, 4:04 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029

  Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.

• May 11, 2026, 4:04 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  Aktis Oncology Q1 2026 net loss $18.3M; cash $538.5M; Phase 1b trials advancing

  Net loss $18.3M vs $15.0M YoY; R&D expense $20.0M (+$4.1M) driven by clinical trial costs.

• April 16, 2026, 7:59 PM ET leadership materiality 0.40 neutral item 5.02item 7.01item 9.01

  Aktis Oncology appoints Glenn Gormley to board; two directors resign

  Glenn Gormley, MD, PhD appointed independent director and co-chair of new Science and Technology Committee, effective April 15, 2026.

• March 30, 2026, 7:59 PM ET other material materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Aktis Oncology: FDA clears IND for AKY-2519; full-year 2025 net loss widens to $63.7M

  FDA cleared IND for AKY-2519 (B7-H3 miniprotein radioconjugate); Phase 1b trial for solid tumors expected mid-2026.

• January 12, 2026, 6:59 PM ET other materiality 0.50 neutral item 5.03item 9.01 ◈ Governance Changes ×2

  Aktis Oncology adopts classified board, supermajority vote, and eliminates written consent post-IPO

  Filed amended charter authorizing 480M shares of common, 10M Class A common, and 10M undesignated preferred stock.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

2 positive 0 negative 3 neutral

source · AKTS on sec.gov